Drug Trial Radar · NCT00384072
Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women
Last checked: Nov 20, 2026Latest source record: Dec 28, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Planned (sponsor's estimate)
Start
May 2006
Primary completion
Not stated
Study completion Sep 2007
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- Female only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of 20 mg of bazedoxifene in comparison to placebo on bone mineral density after 6 months of therapy in a population of postmenopausal Asian women.
Conditions
- Postmenopause
- Osteoporosis
Interventions
bazedoxifene BZA-20Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percent change from baseline in lumbar spine bone mineral density (BMD) after 6 months of treatment
Locations
20 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Nanjing, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Tianjin, China
Site not named
Tianjin, China
Site not named
Tianjin, China
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Suwon, South Korea
Site not named
Kaohsuing, Taiwan
Site not named
Kaoshsuing, Taiwan
Site not named
Tainan, Taiwan
Site not named
Taipei, Taiwan
Site not named
Tapei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.